Ovarian Cancer Coverage from Every Angle

Mansoor Raza Mirza, MD, on Reducing Toxicity Associated With PARP Inhibitors in Ovarian Cancer

Posted: Wednesday, July 3, 2019

Under what circumstances would you switch from one PARP inhibitor to a different one with the goal of reducing a side effect, such as nausea?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.